Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-31

First 31 Last

Share
Profile

Follow
mimmo

2,332 Posts.

448

02/11/22

19:23

Post #: 64553593
Share

Originally posted by Snookered76: ↑

I don't know what will happen to the share price but they must have discovered the commons list requirement will phase out June 2023,and by all intents and purposes the existing CE approved Eugeni platform can be sold then anyway.

So in essence a completely lost cause to chase a trial... Additionally the single geographic outliers detected in the trial must just have arrived in the interim report thay were meant to be used to kick off the commons list approval as well, and it was clearly decided then and there its going to be a waste of time and effort to end up at the same place without a wasteful trial. For the outliers to be isolated you would think it might be a testing method erorr of some sort?
No more trial required, additional $700k in the kitty, and CE approved Eugeni platform for June 2023 it seems.

Expand

Might have been useful to provide a bit more info re outlier results snooker. User error, new virulent and undetected strain?

As someone else mentioned, this "hiccup" probably doesn't enhance the brand.

ADO Price at posting: 5.7¢ Sentiment: Hold Disclosure: Held
1 Upvote

1 Great analysis

Reply

Top Stories

NOX

Noxopharm gets HERACLES autoimmune trials started with first human doses

WCE

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

AII

Inside the depths of Panasqueira: A legacy carved in rock

MGX

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

First 31 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $29.75M

Open	High	Low	Value	Volume
1.1¢	1.1¢	1.1¢	$9.96K	905.4K

Buyers (Bids)

No.	Vol.	Price($)
2	86511	1.1¢

Sellers (Offers)

Price($)	Vol.	No.
1.2¢	1164189	4

View Market Depth

No.	Vol.	Price($)
2	86511	0.011
9	2079500	0.010
7	3324444	0.009
8	2987697	0.008
5	4398167	0.007

Price($)	Vol.	No.
0.012	1164189	4
0.013	820000	3
0.014	1315406	6
0.015	4124116	13
0.016	1628269	3

Last trade - 10.53am 16/07/2025 (20 minute delay)

ADO (ASX) Chart

Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-31

Noxopharm gets HERACLES autoimmune trials started with first human doses

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

Inside the depths of Panasqueira: A legacy carved in rock

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-31

Top Stories

Noxopharm gets HERACLES autoimmune trials started with first human doses

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

Inside the depths of Panasqueira: A legacy carved in rock

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News